PCM
ANIK icon

Pinz Capital Management’s Anika Therapeutics ANIK Stock Holding History

Pinz Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,800
Closed -$121K – 151
2021
Q2 		$121K Buy
+2,800
New +$119K 0.04% 164

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Pinz Capital Management's ANIK Position: Q3 2021 in Review

Pinz Capital Management sold out of Anika Therapeutics (ANIK) in Q3 2021, closing a stake of 2,800 shares — an estimated $121K sold.

Pinz Capital Management first reported a position in ANIK in Q2 2021 and held it in 1 quarter. The position peaked at $121K in Q2 2021. 131 funds tracked by Wall St. Rank hold ANIK as of Q3 2021.

  • Pinz Capital Management reported no remaining Anika Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 2,800 Anika Therapeutics shares in Q3 2021, an estimated $121K.
  • Pinz Capital Management first reported a position in Anika Therapeutics in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Anika Therapeutics position peaked at $121K in Q2 2021.
  • 131 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.